SCHEDULE: Perceptive Converts Trinity Biotech Debt to Equity

Perceptive Advisors and its funds have amended credit agreements with Trinity Biotech plc, converting significant debt obligations into potentially convertible equity, subject to a 9.9% beneficial ownership cap.

Summary

• Perceptive Credit Holdings III, LP and Perceptive Credit Holdings II, LP (the "Funds") have entered into agreements with Trinity Biotech plc to convert outstanding debt and payment obligations into Class A Ordinary Shares, represented by American Depositary Shares (ADSs).
• The Convertible Note, issued to Credit Fund III, evidences outstanding obligations and is convertible into ADSs at a price based on 97% of the volume-weighted average price (VWAP) or a floor price of $1.03 per ADS, up to a $60,000,000 principal conversion cap.
• A Conversion Rights Agreement allows Credit Fund II to convert Milestone Payment Obligations and a $7,500,000 Contingent Payment Obligation into ADSs at similar conversion terms.
• If fully exercised at the $1.03 Floor Price, these conversions could result in the issuance of 69,902,912 ADSs, representing 1,398,058,252 Ordinary Shares.
• All conversions are subject to a "Beneficial Ownership Cap" of 9.9% of Trinity Biotech's total outstanding Ordinary Shares.
• The reporting persons currently beneficially own 1,498,858,251 Ordinary Shares, representing 9.9% of the class, based on 369,329,458 Ordinary Shares outstanding as of June 30, 2025.
• Trinity Biotech also received an additional loan of $5,000,000.
• Accrued and unpaid interest (PIK Interest) was added to the outstanding principal amount.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive for Trinity Biotech as it converts debt to equity, reducing immediate cash obligations and securing additional funding. However, the potential for significant dilution and the market overhang from future share sales introduce a degree of uncertainty for existing shareholders. For Perceptive, it represents a strategic move to potentially realize value from its debt position.

Positives

• Conversion of debt to equity can reduce Trinity Biotech's immediate cash interest payment burden.
• The additional $5,000,000 loan provides further liquidity to Trinity Biotech.
• The agreements provide a structured mechanism for Perceptive to potentially realize value from its debt holdings.

Negatives

• Potential for significant dilution for existing shareholders if Perceptive fully converts its obligations into ADSs, even with the 9.9% cap.
• The conversion price is tied to VWAP, which could result in conversions at lower prices if the stock price declines.
• The Beneficial Ownership Cap limits Perceptive's direct voting influence despite holding a large potential equity stake.

Risks

• **Dilution Risk**: The potential issuance of a substantial number of ADSs (1,398,058,252 Ordinary Shares if fully converted at floor price) could significantly dilute existing shareholders, even though the actual beneficial ownership is capped at 9.9%.
• **Conversion Price Risk**: The conversion price is based on 97% of VWAP, subject to a $1.03 floor, meaning conversions could occur at a discount to market price if the stock trades above the floor.
• **Beneficial Ownership Cap**: The 9.9% cap restricts the voting power of Perceptive, potentially limiting their ability to influence corporate decisions despite their significant economic interest.
• **Market Overhang**: The requirement for Trinity Biotech to file a resale registration statement for up to 55,890,900 ADSs (and potentially more) could create a market overhang, potentially suppressing the stock price.
• **Information Asymmetry**: The agreement not to provide "Inside Information" to Perceptive without consent, subject to limited exceptions, could create an information asymmetry between Perceptive and other investors.

Future Outlook

Perceptive Advisors and its funds have the option, but not the obligation, to convert substantial debt and payment obligations into Trinity Biotech plc ADSs, which could lead to significant equity ownership up to a 9.9% beneficial ownership cap. Trinity Biotech is obligated to facilitate these conversions by reserving shares and filing a resale registration statement for the potential equity.

Industry Context

This filing reflects a common strategy in distressed or growth-stage companies where debt holders convert their positions into equity to improve the company's balance sheet and potentially participate in future upside. For Trinity Biotech, a diagnostics company, this move could alleviate debt burden, but also signals a significant shift in its capital structure and ownership profile, potentially impacting investor perception of its financial health and future equity value.

Comparison to Industry Standards

• The 9.9% beneficial ownership cap is a common defensive measure to avoid triggering certain regulatory thresholds (e.g., poison pill provisions, change of control clauses, or more stringent reporting requirements under Section 13(d) or Irish Takeover Rules).
• Debt-to-equity conversions are a standard financial restructuring tool, often employed by companies facing liquidity challenges or seeking to reduce interest expenses, similar to restructurings seen in other biotech or medical device companies.
• The use of VWAP-based conversion prices with a floor is typical in convertible debt instruments, balancing investor protection with market-based valuation.
• The requirement for a resale registration statement is standard practice when significant amounts of equity are issued to institutional investors, ensuring liquidity for their potential sales.

Corporate Governance

Related Party Transactions

• The issuance of the Convertible Note to Perceptive Credit Holdings III, LP, a fund managed by Perceptive Advisors LLC, which is a reporting person.
• The Conversion Rights Agreement between Trinity Biotech, TRIB Biosensors Inc., and Perceptive Credit Holdings II, LP, another fund managed by Perceptive Advisors LLC.
• The additional $5,000,000 loan provided by Perceptive Credit Holdings III, LP to Trinity Biotech.
• The Registration Rights Agreement between Trinity Biotech and Perceptive Credit Holdings III, L.P. and Perceptive Credit Holdings II, L.P.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution due to the conversion of debt into equity. The 9.9% beneficial ownership cap limits Perceptive's voting power, but the economic interest remains substantial. The market overhang from potential future sales of registered shares could impact share price.
• **Creditors**: The conversion of debt to equity improves Trinity Biotech's balance sheet by reducing outstanding debt, potentially strengthening its credit profile.
• **Company (Trinity Biotech)**: Reduces immediate cash interest payment obligations and provides additional liquidity through a new loan, aiding financial stability. However, it commits to issuing a large number of shares and filing a registration statement.

Next Steps

• Trinity Biotech plc is required to prepare and file a resale registration statement with the SEC by January 14, 2025.
• Trinity Biotech plc must cause the registration statement to be declared effective by the SEC within 60 calendar days of the filing deadline, or 5 trading days after SEC notification of no review.
• Perceptive Credit Holdings III, LP and Perceptive Credit Holdings II, LP may elect to convert their respective obligations into ADSs at their sole discretion.
• Trinity Biotech plc must maintain sufficient authorized and unissued Ordinary Shares to effect the full exercise of conversion rights.

Key Dates

Recommendation

The conversion of significant debt into equity, coupled with an additional loan, provides Trinity Biotech with much-needed financial flexibility and reduces immediate cash outflows for interest payments. This could be seen as a positive step towards stabilizing the company's balance sheet. However, the potential for substantial dilution from the conversion of up to 1.4 billion Ordinary Shares (even if capped at 9.9% beneficial ownership) and the impending resale registration statement create a significant overhang on the stock. While the debt reduction is favorable, the dilution risk and the uncertainty surrounding Perceptive's future conversion and selling activities warrant a 'hold' recommendation. Investors should monitor the actual conversion rates and market absorption of any newly issued shares.

Keywords

Trinity Biotech, Perceptive Advisors, SEC Filing, Schedule 13D, Convertible Note, Debt Conversion, Equity Conversion, ADSs, Ordinary Shares, Beneficial Ownership, Dilution, Credit Agreement, Registration Rights, Corporate Governance, Financial Restructuring